Skip to main content

Table 1 Baseline characteristics of patients with AS, PsA, uSpA and GP comparators at start of follow-up

From: Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study

  AS (n = 6448) PsA (n = 16,063) uSpA (n = 5190) GP (n = 266,435)
Sex
 Males 4390 (68.1) 7217 (44.9) 2325 (44.8) 131,807 (49.5)
 Females 2058 (31.9) 8846 (55.1) 2865 (55.2) 134,628 (50.5)
Age (years)
 Mean (SD) 50.0 (13.9) 53.2 (13.8) 44.7 (13.3) 53.5 (15.9)
 18–29 years 488 (7.6) 761 (4.7) 691 (13.3) 18,465 (6.9)
 30–39 years 1120 (17.4) 2047 (12.7) 1255 (24.2) 36,805 (13.8)
 40–49 years 1452 (22.5) 3368 (21.0) 1406 (27.1) 52,122 (19.6)
 50–59 years 1670 (25.9) 4385 (27.3) 1085 (20.9) 63,559 (23.9)
 60–69 years 1209 (18.8) 3638 (22.6) 583 (11.2) 52,626 (19.8)
 70–79 years 414 (6.4) 1422 (8.9) 132 (2.5) 27,259 (10.2)
  ≥ 80 years 95 (1.5) 442 (2.8) 38 (0.7) 15,599 (5.9)
Start of follow-up
 2006–2007 4938 (76.6) 11,926 (74.2) 3725 (71.8) 266,234 (99.9)
 2008–2010 1510 (23.4) 4137 (25.8) 1465 (28.2) 201 (0.1)
Level of education
 -≤9 years 1423 (22.1) 4039 (25.1) 804 (15.5) 68,776 (25.8)
 -10–12 years 3096 (48.0) 7983 (49.7) 2566 (49.4) 119,681 (44.9)
 ->12 years 1858 (28.8) 3931 (24.5) 1789 (34.5) 74,587 (28.0)
 -Missing 71 (1.1) 110 (0.7) 31 (0.6) 3391 (1.3)
SpA-related comorbiditiesa
 Anterior uveitis 1342 (20.8) 252 (1.6) 771 (14.9) 1156 (0.4)
 Inflammatory bowel disease 514 (8.0) 346 (2.2) 269 (5.2) 2565 (1.0)
 Psoriasis 145 (2.2) 15,873 (98.8) 162 (3.1) 2190 (0.8)
SpA-related medicationsb
 Any DMARD 1599 (24.8) 6659 (41.5) 1579 (30.4) 2542 (1.0)
  -TNF inhibitors 545 (8.5) 758 (4.7) 279 (5.4) 268 (0.1)
  -Methotrexate 494 (7.7) 5094 (31.7) 609 (11.7) 1104 (0.4)
  -Sulfasalazin 798 (12.4) 1396 (8.7) 877 (16.9) 493 (0.2)
 NSAIDs 3543 (54.9) 7801 (48.6) 2804 (54.0) 28,467 (10.7)
 Prednisone 659 (10.2) 2133 (13.3) 778 (15.0) 4234 (1.6)
Other comorbiditiesa
 Ischemic heart disease 468 (7.3) 1091 (6.8) 182 (3.5) 14,849 (5.6)
  -ACS 256 (4.0) 576 (3.6) 94 (1.8) 8714 (3.3)
 Composite stroke 201 (3.1) 527 (3.3) 84 (1.6) 8954 (3.4)
  -Ischemic stroke 92 (1.4) 265 (1.6) 49 (0.9) 5009 (1.9)
  -Hemorrhagic stroke 41 (0.6) 100 (0.6) 14 (0.3) 1412 (0.5)
  -TIA 77 (1.2) 185 (1.2) 28 (0.5) 2951 (1.1)
 Venous thromboembolism 115 (1.8) 347 (2.2) 80 (1.5) 3835 (1.4)
 Diabetes 311 (4.8) 1025 (6.4) 144 (2.8) 10,118 (3.8)
 COPD 122 (1.9) 317 (2.0) 48 (0.9) 3507 (1.3)
 Atrial fibrillation or flutter 264 (4.1) 513 (3.2) 87 (1.7) 7430 (2.8)
 Other atherosclerotic disease 210 (3.3) 581 (3.6) 101 (1.9) 8318 (3.1)
Dispensed prescriptionsb
 Oral antidiabetics or insulin 274 (4.2) 1077 (6.7) 123 (2.4) 11,372 (4.3)
 Antihypertensive 1794 (27.8) 4853 (30.2) 846 (16.3) 59,053 (22.2)
 Statins 657 (10.2) 1871 (11.6) 307 (5.9) 23,180 (8.7)
 Aspirin 557 (8.6) 1519 (9.5) 230 (4.4) 23,655 (8.9)
 Warfarin 174 (2.7) 277 (1.7) 52 (1.0) 4328 (1.6)
  1. Age are given in mean (SD). All other data are presented in number (%)
  2. AS ankylosing spondylitis, PsA psoriatic arthritis, uSpA undifferentiated spondyloarthritis, GP general population, DMARD disease-modifying antirheumatic drug, NSAIDs nonsteroidal anti-inflammatory drugs, ACS acute coronary syndrome, TIA transient ischemic attack, COPD chronic obstructive pulmonary disease
  3. aPrevalent comorbidity at baseline, defined by identification of specified ICD codes in the National Patient Register prior to start of follow-up
  4. bDispensed prescription in Prescribed Drug Register or intravenous bDMARDs in Swedish Rheumatology Quality register within 6 months prior to start of follow-up